Licensed vaccine
ActHIB
FDA-licensed vaccine · Sanofi Pasteur Inc. · STN 103935
Key facts
| Trade name | ActHIB |
|---|---|
| Proper name | Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) |
| Manufacturer | Sanofi Pasteur Inc. |
| Submission tracking number (STN) | 103935 |
| Recent FDA documents | October 13, 2022 Approval Letter - ActHIB, July 27, 2022 Approval Letter - ActHIB, May 24, 2019 Approval Letter - ActHIB, Package Insert - ActHIB, Supporting Documents older than three years - ActHIB |
| FDA page updated | Oct 14, 2022 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: